Anti C38 rally

(56)

Is re-treatment possible with anti-CD38 therapies?

(3:16)

Anti-CD38 monoclonal antibodies – a new drug class for treating myeloma

(1:12)

The impact of the addition of anti-CD38 monoclonal antibodies to the frontline treatment of myeloma

(56)

Anti-CD38 immunotherapy treatment for multiple myeloma

(7:16)

A retrospective study analyzing outcomes of patients with anti-CD38 refractory myeloma

(57)

Mechanistic insights into the resistance to anti-CD38 therapy

(4:43)

Current research on anti-CD38 CAR T-cell therapies

(1:9)

How Anti Personnel Landmine Works (M-16)

(2:2)

Dr. Angela Dispenzieri Discusses Anti-CD38 Monoclonal Antibodies in Myeloma

(1:19)

Safety Profile of Anti-CD38 Monoclonal Antibodies in MM

(4:41)

Anti CD38 and anti SLAMF7 Therapeutics: Are they ready to go upfront?

(19:1econd)

Mechanisms of action of CD38 antibodies in myeloma

(1:45)

Mezagitamab: an anti-CD38 antibody for R/R MM

(1:14)

Stem cell collection in patients with multiple myeloma treated with anti-CD38 monoclonal antibodies

(2:31)

What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma

(47:31)

Dr. Noopur Raje Discusses Anti-CD38 Antibodies in Myeloma

(34)

Anti-CD38 CAR NK-cells: an off-the shelf therapy for multiple myeloma

(3:42)

The PTKM-1R: Russia's most advanced anti-tank mine explained

(2:10)

The management of patients with myeloma who are anti-CD38 refractory

(1:28)